Search ARM

RootPath is a Massachusetts-based preclinical-stage biotechnology company pioneering synthetic immunology and its therapeutic applications. With our Synthetic Immunology platform, we are the only group in the world that can ‘Read’, ‘Write’ and ‘Mine’ the immune system fast and inexpensively enough to enable personalized discovery of therapeutic TCRs. In particular, our PathFinder technology allows us to synthesize >10,000 TCRs at the cost of <$1/TCR, marking a 100-fold cost reduction from existing technologies. Our lead program is a personalized TCR-programmed cell therapy for solid tumors. Future opportunities include infectious and autoimmune diseases. RootPath was launched in 2017 by Ventures and has raised $18M in seed and Series A financing.

Contact RootPath
Visit Website